HIV 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 단계별, 시험 설계별, 스폰서별, 지역별, 부문별 예측(2025-2030년)

HIV Clinical Trials Market Growth & Trends:

The global HIV clinical trials market size is estimated to reach USD 2.11 billion by 2030, registering to grow at a CAGR of 5.8% from 2025 to 2030 according to a new report by Grand View Research, Inc. The main drivers of this market are increasing HIV vaccine trials, increased R&D activities for HIV clinical trials, and rising HIV infection awareness, which leads to a large number of patients enrolling in clinical trials. During the COVID-19 pandemic, there was a halt in the market growth.

This decrease in HIV and AIDS clinical trials is due to stay-at-home orders by the government to prevent COVID-19 that led to canceled and delayed trials. It also includes disruption in patient recruitment, hurdles in the conduction of clinical trials, and rapid study for the development of vaccines and medical products for the prevention of COVID-19 that lead to detrimental effects in HIV clinical trial studies. However, these impacts were significantly reduced by adopting strategic measures taken by the clinical trial conducting organization, regulatory authorities, and government bodies.

According to the WHO, in 2020, there were around 37.7 million people infected with HIV infection. To reduce this number, increasing funding and partnerships by biotechnology and pharmaceutical firms have been observed. Moreover, increasing initiatives are being taken by the government to find treatment and spread awareness regarding this disease. For instance, in October 2021, Samsung BioLogics collaborated with Enzolytics Inc. This partnership aims to manufacture Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies.

However, a lack of awareness regarding HIV clinical research trials and the availability of treatments for preventing it are factors that are hindering the growth of this market. According to a report by BioMed Central Ltd. in Europe, out of 467 participants, about one-third of them were not aware of the HIV infection. As a result, ignorance and unawareness regarding the disease will prevent admission to an HIV clinical trial.

HIV Clinical Trials Market Report Highlights:

• In 2024, the phase III segment dominated the HIV clinical trials industry, accounting for a revenue share of 30.0%. Phase I studies help to assess the drug's safety & toxicity at different levels of dose & determine drug pharmacokinetics.
• In 2024, the interventional studies segment dominated the HIV clinical trials industry, accounting for a revenue share of 69.8%.
• The pharmaceutical and biopharmaceutical companies segment accounted for the largest market share in 2024.
• North America HIV clinical trials market dominated the global market in 2024 with the largest share of 47.3%. This can be attributed to the increased number of HIV clinical trials being conducted in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. HIV Clinical Trials Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising drug approvals and new product launches
    • 3.2.1.2. Increasing R&D initiatives by biotechnology & pharmaceutical companies
    • 3.2.1.3. Increasing incidence of HIV
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of awareness and access to treatment for HIV Infection
    • 3.2.2.2. Stringent regulations
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. HIV Clinical Trials Market: Phase Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global HIV Clinical Trials Market: Phase Movement Analysis
• 4.3. Global HIV Clinical Trials Size & Trend Analysis: by Phase, 2018 to 2030 (USD Million)
• 4.4. Phase I
  • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Phase II
  • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Phase III
  • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Phase IV
  • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. HIV Clinical Trials Market: Study Design Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global HIV Clinical Trials Market: Study Design Movement Analysis
• 5.3. Global HIV Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
• 5.4. Interventional Studies
  • 5.4.1. Interventional studies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Observational Studies
  • 5.5.1. Observational studies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Expanded Access Studies
  • 5.6.1. Expanded access studies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. HIV Clinical Trials Market: Sponsor Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global HIV Clinical Trials Market: Sponsor Movement Analysis
• 6.3. Global HIV Clinical Trials Size & Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biopharmaceutical Companies
  • 6.4.1. Pharmaceutical & biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Non-Profit Organizations
  • 6.5.1. Non-profit organizations market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. HIV Clinical Trials Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. PPD Inc.
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. IQVIA Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Parexel International Corporation.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. ICON plc
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Syneos Health
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. WuXi AppTec
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Janssen Global Services, LLC
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Gilead Sciences, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Bionor Holding AS
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Charles River Laboratories
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. GSK plc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Service benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. SGS SA
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Service benchmarking
    • 8.3.12.4. Strategic initiatives